FAQ Library

FAQ Library published on October 24, 2019
Join Dr. Drake as he covers the risk of developing complications in the skeleton after a patient with multiple myeloma achieves complete remission.
FAQ Library published on May 8, 2019
Join Dr. Philip McCarthy as he explains the development of central nervous system toxicity after cytokine-release syndrome (CRS), and also whether CRS affects CAR T cells.
FAQ Library published on April 24, 2019
In this activity, Dr. Philip McCarthy discusses cytokine-release syndrome and the most common treatment approaches.
FAQ Library published on December 3, 2018
Dr. Holstein explains the risk of developing an SPM on lenalidomide maintenance vs. the benefit of maintenance in delaying progression or death from myeloma, and how to counsel patients.
FAQ Library published on November 8, 2018
Dr. Holstein reviews the impact maintenance therapy has on patient outcomes, and what factors you must consider when prescribing maintenance therapy.
FAQ Library published on October 24, 2018
Dr. Richardson provides a brief update on recent developments in CAR-T therapy in patients with multiple myeloma, and what we can see on the horizon.
FAQ Library published on October 10, 2018
Dr. Richardson discusses an area of unmet need in relapsed/refractory multiple myeloma: how to identify treatment options for so-called "quad-refractory" patients.
FAQ Library published on September 24, 2018
Dr. Davies details the tools and technologies used to define and detect minimal residual disease, and discusses how to proceed once you know your patient's MRD status.
FAQ Library published on September 10, 2018
Dr. McCarthy explains the evolving recommendations for how and when to use herpes zoster vaccine in multiple myeloma patients, both active and newly diagnosed.
FAQ Library published on August 20, 2018
Dr. Raje discusses how we can expect to see more drugs and new combinations utilized in the upfront setting, as approvals in the relapsed/refractory setting increase.
Page 2 of 16
Results 11 - 20 of 151